Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:1319
Name brain cancer
Definition A central nervous system cancer that is characterized by the growth of abnormal cells in the tissues of the brain.
Source DiseaseOntology.org
Alt Ids DOID:2125 DOID:3543 DOID:911 DOID:6649 DOID:2126
Path disease disease of cellular proliferation cancer organ system cancer nervous system cancer central nervous system cancer brain cancer

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status
NCT01386580 Phase Ib/II 2B3-101 2B3-101 + Trastuzumab An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma. Completed
NCT01518413 Phase I Irinotecan + Sorafenib Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors Completed
NCT01753713 Phase II Dovitinib Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma Completed
NCT02015728 Phase I Erlotinib Everolimus Dasatinib Etoposide + Temozolomide Sorafenib Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors Unknown status
NCT02130869 Phase I Bendamustine + Cytarabine + Etoposide Busulfan + Hu14.18K322A Aldesleukin + Melphalan + Sargramostim Filgrastim Carboplatin + Etoposide A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas Completed
NCT02502708 Phase I Indoximod Temozolomide Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Primary Malignant Brain Tumors Completed
NCT02574728 Phase II Celecoxib + Cyclophosphamide + Etoposide + Sirolimus Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors Recruiting
NCT02644291 Phase I Mebendazole Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors Recruiting
NCT02644460 Phase I Abemaciclib Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors Recruiting
NCT02698254 Phase 0 Bevacizumab Radiation Therapy in Treating Patients With Recurrent Brain Tumors Who Have Undergone Previous Radiation Therapy Recruiting
NCT03068832 Phase I Poly ICLC Neoepitope-based Personalized Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors Not yet recruiting
NCT03330197 Phase I Ad-RTS-IL-12 plus AL A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors or DIPG Recruiting
NCT03434262 Phase I Ribociclib + Trametinib Filgrastim + Gemcitabine + Ribociclib Ribociclib + Sonidegib SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors Recruiting
NCT03478462 Phase I CLR 131 Dose Escalation Study of CLR 131 in Children and Adolescents With Relapsed or Refractory Malignant Brain Cancer, Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma Recruiting
NCT03510208 Phase Ib/II Panitumumab Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery Recruiting
NCT03668847 Phase II DM-CHOC-PEN DM-CHOC-PEN for Brain Tumors in AYA Subjects Recruiting
NCT03967093 Phase I BXQ-350 A Study of BXQ-350 in Children and Young Adults With Relapsed Solid Tumors Active, not recruiting
NCT04334863 Phase I WP1066 AflacST1901: Peds WP1066 Recruiting
NCT04525014 Phase I Irinotecan + RRx-001 + Temozolomide RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors (PIRATE) Not yet recruiting